Online inquiry

IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4789MR)

This product GTTS-WQ4789MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets DPP4 gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001379604.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1803
UniProt ID P27487
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4789MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1740MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ14291MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ6634MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ5089MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ9984MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ14033MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ14685MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ5321MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW